ClinicalTrials.gg
CompletedNCT03412006CADA DIAUpdated Mar 3, 2022

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

A Phase 2 interventional study of Fulacimstat (BAY1142524) and Placebo in Diabetic Kidney Disease, sponsored by Bayer. Completed at 27 sites in 7 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Diabetic Nephropathies with a site in Israel — none open to participants now, none under way, none of them phase 3. Diabetic Nephropathies · Israel.

Enrollment
9th of 13
152 · median 265
Started
2018
the only one that year
Phase 2
7 of 14
none open now
Registered
11th of 14
by date
Lead sponsor
4 of 14
Bayer

Among the 14 studies in Diabetic Nephropathies with a site in Israel, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 2, and was the 11th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 111 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

None of the 14 studies in Diabetic Nephropathies with a site in Israel is open now. The open studies under Diabetic Nephropathies, anywhere →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Diabetic Nephropathies with a site in Israel as a file.
02

Study summary

The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in type II diabetic patients with a clinical diagnosis of diabetic kidney disease. BAY1142524 or placebo will be given on top of evidence-based standard of care for diabetic kidney disease. Primary objective is the analysis of first signs of efficacy as determined by favourable changes in urinary albumin creatinine ratio. Secondary objective is the analysis of safety and tolerability as evidenced by the incidence and severity of adverse events. 64 valid patients have to complete treatment with verum and 32 valid patients have to complete treatment with placebo.

03

Conditions studied

  • Diabetic Kidney Disease

Keywords

  • type II diabetes
  • diabetic kidney disease
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 2 Diabetes Mellitus and a clinical diagnosis of diabetic kidney disease (DKD) (as judged by the investigator) who have finished their up-titration with an angiotensin receptor blocker (ARB) or an ACEI (angiotensin-converting enzyme inhibitor) to their maximum tolerated dose at least 3 months prior to the screening visit, whereby the maximum tolerated dose has to be at least as high as the minimal recommended dose of an ARB or ACEI according to local and/or international guidelines. Patients have to be treated with an ARB or ACEI, but not with both simultaneously, without any adjustments to this therapy for at least 4 weeks prior to the screening visit.
  • UACR >50 mg/g and \<3000 mg/g in 2 out of 3 consecutive morning void samples at the screening and the baseline visit
  • estimated (eGFR) ≥30 mL/min/1.73 m*2 and \<90 mL/min/1.73 m*2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) at the screening visit and the baseline visit

Exclusion criteria

Exclusion Criteria:

  • Non-DKD if it is the main diagnosis contributory to chronic kidney disease (CKD), as judged by the investigator
  • Known bilateral clinical relevant renal artery stenosis (>75%)
  • (NYHA) Class IV
  • Acute kidney injury or dialysis within the last 3 months before the screening visit
  • Renal replacement therapy during study conduct
  • Renal allograft in place or a scheduled kidney transplant during study conduct
  • Stroke, transient ischemic cerebral attack, acute coronary syndrome, or hospitalization for heart failure in the last 3 months prior to screening visit
  • hepatic dysfunction
  • Uncontrolled hypertension as evidenced by systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg (mean of triplicate values at the screening or baseline visit)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Fulacimstat (BAY1142524)

    Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition

    Drug: Fulacimstat (BAY1142524)

  • Placebo comparator
    Placebo

    Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition

    Drug: Placebo

Interventions

  • 25 mg BAY1142524 are given twice daily over a treatment period of 6 months

  • DrugPlacebo

    Matching placebo tablets are given twice daily over a treatment period of 6 months

06

What researchers measure

Primary outcomes

  1. Change in urinary albumin to creatinine ratio (UACR)

    The ratio of albumin to creatinin will be determined in first morning void urine at baseline (before treatment start) and after 6 months of treatment

    Time frame: Baseline and at 6 months

Secondary outcomes

  1. Number of patients with treatment-emergent adverse event

    Time frame: From first intake of study drug up to 3 days after last administration of study drug

  2. Number of patients with serious adverse events

    Time frame: From first intake of study drug up to 3 days after last administration of study drug

07

Study locations

27 sites
  • Med Centre Diamedical 2013
    Dimitrovgrad, 6400, Bulgaria
  • MCOMH Preventsia-2000
    Stara Zagora, 6000, Bulgaria
  • Med. Center Equita
    Varna, 9000, Bulgaria
  • Steno Diabetes Center Copenhagen
    Gentofte, 2730, Denmark
  • Nordsjællands Hospital
    Hillerød, 3400, Denmark
  • Rigshospitalet
    København, 2100, Denmark
  • Pihlajalinna ITE Kuopio
    Kuopio, 70100, Finland
  • Terveystalo Oulu
    Oulu, FI-90100, Finland
  • TAYS TKI Keskus Tutkimusvastaanotto
    Tampere, 33520, Finland
  • Turun yliopistollinen keskussairaala, kantasairaala
    Turku, FIN-20520, Finland
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Edith Wolfson Medical Center
    Holon, 5822012, Israel
  • Hadassah Hebrew University Hospital Ein Kerem
    Jerusalem, 9112001, Israel
  • The Nazareth Trust Hospital EMMS
    Nazareth, 16100, Israel
  • DMC - Diabetes Medical Center
    Tel Aviv, 6937947, Israel
  • Shamir Medical Center (Assaf Harofeh)
    Zerifin, 7030000, Israel
  • A.O.U. Policlinico Federico II Napoli
    Napoli, Campania 80131, Italy
  • Univ. Alma Mater - Dip. Medicina Spec, Diagnostica e Sperim
    Bologna, Emilia-Romagna 40138, Italy
  • IRCCS Casa Sollievo della Sofferenza
    Foggia, Puglia 71013, Italy
  • A.O.U. di Padova
    Padova, Veneto 35128, Italy
  • Complexo Hospitalario Universitario de Ferrol
    Ferrol, A Coruña 15405, Spain
  • Hospital de Galdakao
    Galdakao, Vizcaya 48960, Spain
  • Hospital Fundació Puigvert
    Barcelona, 08025, Spain
  • Centralsjukhuset Kristianstad
    Kristianstad, 29185, Sweden
  • Akardo MedSite AB
    Stockholm, 114 46, Sweden
  • S3 Clinical Research Centers
    Vällingby, 162 68, Sweden
  • Universitetssjukhuset Örebro
    Örebro, 701 85, Sweden
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Oct 2019, 20 months.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 20 months is close to that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2018
First posted
Jan 26, 2018
StartActual
Feb 2, 2018
Primary completionActual
Oct 2, 2019
CompletionActual
Oct 10, 2019
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03412006
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 26, 2018
Start date
Feb 2, 2018
Primary completion
Oct 2, 2019
Completion
Oct 10, 2019
Last update
Mar 3, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulacimstat

Start the discussion